Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.The international journal of neuropsychopharmacology · 2020Pooled it
- Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.JAMA network open · 2020Pooled it
- Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.The lancet. Psychiatry · 2020Pooled it
- Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.Cannabis and cannabinoid research · 2023Trial
- The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.Addiction (Abingdon, England) · 2023Trial
- Adolescents are more sensitive than adults to acute behavioral and cognitive effects of THC.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).Psychopharmacology · 2022Trial
- In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers.Psychopharmacology · 2020Trial
- Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.Neuropharmacology · 2018Trial
- Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.Biological psychiatry · 2015Trial
- Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Effects of 20 mg oral Δ(9) -tetrahydrocannabinol on the olfactory function of healthy volunteers.British journal of clinical pharmacology · 2014Trial
- Acute effects of THC on time perception in frequent and infrequent cannabis users.Psychopharmacology · 2013Trial
- Visual P300 and Risk for Psychosis Onset in Youth at Clinical High Risk.Biological psychiatry · 2026Article
- Joint effects of human immunodeficiency virus (HIV) and cannabis on neurocognition.Neuropsychology · 2025Article
- A Computational Account of the Development and Evolution of Psychotic Symptoms.Biological psychiatry · 2025Review
- Article
- P300 in schizophrenia: Then and now.Biological psychology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Cannabinoids induce a host of perceptual alterations and cognitive deficits in humans. However, the neural correlates of these deficits have remained elusive. The current study examined the acute, dose-related effects of delta-9-tetrahydrocannabinol (Δ⁹-THC) on psychophysiological indices of information processing in humans. Healthy subjects (n=26) completed three test days during which they received intravenous Δ⁹-THC (placebo, 0.015 and 0.03 mg/kg) in a within-subject, double-blind, randomized, cross-over, and counterbalanced design. Psychophysiological data (electroencephalography) were collected before and after drug administration while subjects engaged in an event-related potential (ERP) task known to be a valid index of attention and cognition (a three-stimulus auditory 'oddball' P300 task). Δ⁹-THC dose-dependently reduced the amplitude of both the target P300b and the novelty P300a. Δ⁹-THC did not have any effect on the latency of either the P300a or P300b, or on early sensory-evoked ERP components preceding the P300 (the N100). Concomitantly, Δ⁹-THC induced psychotomimetic effects, perceptual alterations, and subjective 'high' in a dose-dependent manner. Δ⁹-THC -induced reductions in P3b amplitude correlated with Δ⁹-THC-induced perceptual alterations. Lastly, exploratory analyses examining cannabis use status showed that whereas recent cannabis users had blunted behavioral effects to Δ(9)-THC, there were no dose-related effects of Δ⁹-THC on P300a/b amplitude between cannabis-free and recent cannabis users. Overall, these data suggest that at doses that produce behavioral and subjective effects consistent with the known properties of cannabis, Δ⁹-THC reduced P300a and P300b amplitudes without altering the latency of these ERPs. Cannabinoid agonists may therefore disrupt cortical processes responsible for context updating and the automatic orientation of attention, while leaving processing speed and earlier sensory ERP components intact. Collectively, the findings suggest that CB1R systems modulate top-down and bottom-up processing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.